hydroxychloroquine has been researched along with Malignant Melanoma in 12 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma." | 9.30 | FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. ( Aleman, TS; Amaravadi, RK; Bowman, S; Edelstein, ID; Gangadhar, TC; Huang, A; Kim, BJ; Mitnick, S; Nichols, CW; Nti, AA; Sandhu, HS; Schuchter, LM; Serrano, LW; Song, D; Uyhazi, KE; Zhou, EJ, 2019) |
| "To characterise the incidence rate of skin cancer associated with methotrexate and hydroxychloroquine in older adults with rheumatoid arthritis (RA)." | 8.31 | Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study. ( Chen, SK; Desai, RJ; Gautam, N; Glynn, RJ; He, M; Kim, SC; Lee, H; Vine, SM; Weinblatt, ME, 2023) |
| " Here, we prepared R8-dGR peptide modified paclitaxel (PTX) and hydroxychloroquine (HCQ) co-loaded liposomes (PTX/HCQ-R8-dGR-Lip) for enhanced delivery by recognizing integrin αvβ3 receptors and neuropilin-1 receptors on B16F10 melanoma cells." | 7.88 | Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways. ( He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z, 2018) |
| "Hydroxychloroquine was suspected of causing an anxiety/psychotic disorder in one patient." | 7.11 | A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. ( Awada, G; Fasolino, G; Kruse, V; Neyns, B; Schwarze, JK; Tijtgat, J, 2022) |
| "To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma." | 5.30 | FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. ( Aleman, TS; Amaravadi, RK; Bowman, S; Edelstein, ID; Gangadhar, TC; Huang, A; Kim, BJ; Mitnick, S; Nichols, CW; Nti, AA; Sandhu, HS; Schuchter, LM; Serrano, LW; Song, D; Uyhazi, KE; Zhou, EJ, 2019) |
| "To characterise the incidence rate of skin cancer associated with methotrexate and hydroxychloroquine in older adults with rheumatoid arthritis (RA)." | 4.31 | Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study. ( Chen, SK; Desai, RJ; Gautam, N; Glynn, RJ; He, M; Kim, SC; Lee, H; Vine, SM; Weinblatt, ME, 2023) |
| " Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of chloroquine derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma." | 3.96 | PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. ( Amaravadi, RK; Attanasio, J; Gabrilovich, DI; Gimotty, PA; Harper, SL; Jain, V; Lee, JJ; Liu, S; Mastio, J; Nicastri, MC; Noguera-Ortega, E; Ojha, R; Piao, S; Rebecca, VW; Ronghe, A; Sharma, G; Speicher, DW; Wherry, EJ; Winkler, JD; Xu, X, 2020) |
| " Here, we prepared R8-dGR peptide modified paclitaxel (PTX) and hydroxychloroquine (HCQ) co-loaded liposomes (PTX/HCQ-R8-dGR-Lip) for enhanced delivery by recognizing integrin αvβ3 receptors and neuropilin-1 receptors on B16F10 melanoma cells." | 3.88 | Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways. ( He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z, 2018) |
| "Hydroxychloroquine was suspected of causing an anxiety/psychotic disorder in one patient." | 3.11 | A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. ( Awada, G; Fasolino, G; Kruse, V; Neyns, B; Schwarze, JK; Tijtgat, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mehnert, JM | 2 |
| Mitchell, TC | 1 |
| Huang, AC | 1 |
| Aleman, TS | 2 |
| Kim, BJ | 2 |
| Schuchter, LM | 4 |
| Linette, GP | 1 |
| Karakousis, GC | 1 |
| Mitnick, S | 2 |
| Giles, L | 1 |
| Carberry, M | 1 |
| Frey, N | 1 |
| Kossenkov, A | 1 |
| Groisberg, R | 1 |
| Hernandez-Aya, LF | 1 |
| Ansstas, G | 1 |
| Silk, AW | 1 |
| Chandra, S | 1 |
| Sosman, JA | 1 |
| Gimotty, PA | 2 |
| Mick, R | 1 |
| Amaravadi, RK | 5 |
| Awada, G | 1 |
| Schwarze, JK | 1 |
| Tijtgat, J | 1 |
| Fasolino, G | 1 |
| Kruse, V | 1 |
| Neyns, B | 1 |
| Lee, H | 1 |
| Chen, SK | 1 |
| Gautam, N | 1 |
| Vine, SM | 1 |
| He, M | 1 |
| Desai, RJ | 1 |
| Weinblatt, ME | 1 |
| Glynn, RJ | 1 |
| Kim, SC | 1 |
| Yekedüz, E | 1 |
| Dursun, B | 1 |
| Aydın, GÇ | 1 |
| Yazgan, SC | 1 |
| Öztürk, HH | 1 |
| Azap, A | 1 |
| Utkan, G | 1 |
| Ürün, Y | 1 |
| Sharma, G | 1 |
| Ojha, R | 1 |
| Noguera-Ortega, E | 1 |
| Rebecca, VW | 1 |
| Attanasio, J | 1 |
| Liu, S | 1 |
| Piao, S | 2 |
| Lee, JJ | 1 |
| Nicastri, MC | 1 |
| Harper, SL | 1 |
| Ronghe, A | 1 |
| Jain, V | 1 |
| Winkler, JD | 1 |
| Speicher, DW | 1 |
| Mastio, J | 1 |
| Xu, X | 1 |
| Wherry, EJ | 1 |
| Gabrilovich, DI | 1 |
| Krueger, J | 1 |
| Santinon, F | 1 |
| Kazanova, A | 1 |
| Issa, ME | 1 |
| Larrivee, B | 1 |
| Kremer, R | 1 |
| Milhalcioiu, C | 1 |
| Rudd, CE | 1 |
| Nti, AA | 1 |
| Serrano, LW | 1 |
| Sandhu, HS | 1 |
| Uyhazi, KE | 1 |
| Edelstein, ID | 1 |
| Zhou, EJ | 1 |
| Bowman, S | 1 |
| Song, D | 1 |
| Gangadhar, TC | 1 |
| Huang, A | 1 |
| Nichols, CW | 1 |
| Yin, S | 1 |
| Xia, C | 1 |
| Wang, Y | 1 |
| Wan, D | 1 |
| Rao, J | 1 |
| Tang, X | 1 |
| Wei, J | 1 |
| Wang, X | 1 |
| Li, M | 1 |
| Zhang, Z | 1 |
| Liu, J | 1 |
| He, Q | 1 |
| Xiao, M | 1 |
| Noman, MZ | 1 |
| Menard, L | 1 |
| Chevigne, A | 1 |
| Szpakowska, M | 1 |
| Bosseler, M | 1 |
| Ollert, M | 1 |
| Berchem, G | 1 |
| Janji, B | 1 |
| Rangwala, R | 2 |
| Chang, YC | 2 |
| Hu, J | 1 |
| Algazy, KM | 1 |
| Evans, TL | 2 |
| Fecher, LA | 2 |
| Torigian, DA | 1 |
| Panosian, JT | 1 |
| Troxel, AB | 2 |
| Tan, KS | 2 |
| Heitjan, DF | 2 |
| DeMichele, AM | 2 |
| Vaughn, DJ | 1 |
| Redlinger, M | 1 |
| Alavi, A | 1 |
| Kaiser, J | 2 |
| Pontiggia, L | 2 |
| Davis, LE | 2 |
| O'Dwyer, PJ | 2 |
| Leone, R | 1 |
| Kramer, A | 1 |
| Rodgers, G | 1 |
| Gallagher, M | 1 |
| Nathanson, KL | 1 |
| Xie, X | 1 |
| White, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
1 review available for hydroxychloroquine and Malignant Melanoma
| Article | Year |
|---|---|
Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots.
Topics: Adipogenesis; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Biomarkers; Che | 2018 |
5 trials available for hydroxychloroquine and Malignant Melanoma
6 other studies available for hydroxychloroquine and Malignant Melanoma
| Article | Year |
|---|---|
Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2023 |
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Antiviral Agents; Azithromycin; Betacoronavirus; Coronav | 2020 |
PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Hydroxychlor | 2020 |
Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
Topics: Animals; Azithromycin; Cell Line, Tumor; Drug Antagonism; Hydroxychloroquine; Immune Checkpoint Inhi | 2021 |
Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line | 2018 |
Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.
Topics: Allosteric Regulation; Animals; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proli | 2013 |